Search
Ripasudil
go.drugbank.com/drugs/DB13165InvestigationalRipasudil, as hydrochloride hydrate (K-115), is a specifc Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor used for the treatment of glaucoma and ocular hypertension. It was first approved for treatment in Japan in S...
Disitamab vedotin
go.drugbank.com/drugs/DB17208InvestigationalDisitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.[A254721]
MGN-4893
go.drugbank.com/drugs/DB17338ExperimentalMGN-4893 is an inhibitor of microRNA-451. In February 2011, it was granted FDA orphan designation for the treatment of polycythemia vera.[L47356]
Ixmyelocel-T
go.drugbank.com/drugs/DB17601InvestigationalIxmyelocel-T is an expanded, autologous multicellular therapy cultured from bone-marrow mononuclear cells. Developed by Vericel Corporation, it is being investigated for cardiomyopathy.
ADVM-062
go.drugbank.com/drugs/DB18341ExperimentalADVM-062 is an adeno-associated virus vector carrying complementary deoxyribonucleic acid encoding the human long-wave-sensitive opsin 1 (AAV.7m8-L-opsin)
Glembatumumab vedotin
go.drugbank.com/drugs/DB05996InvestigationalA conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
Anisomycin
go.drugbank.com/drugs/DB07374ExperimentalAnisomycin (sometimes known as flagecidin), is an antibiotic retrieved from the bacteria _Streptomyces griseolus_. This drug acts to inhibit bacterial protein and DNA synthesis.
Pentanal
go.drugbank.com/drugs/DB01919ExperimentalPentanal is an aldehyde that is liquid at room temperature. It is occasionally a minor ingredient in some cosmetic products like perfumes.[L53886,L53891]
Detirelix
go.drugbank.com/drugs/DB19488ExperimentalDetirelix has a monoisotopic molecular weight of 1536.78 Da.
Terdecamycin
go.drugbank.com/drugs/DB19720ExperimentalTerdecamycin has a monoisotopic molecular weight of 585.31 Da.